By Mill Chart
Last update: Nov 12, 2024
Our stock screening tool has pinpointed CATALYST PHARMACEUTICALS INC (NASDAQ:CPRX) as an undervalued stock option. NASDAQ:CPRX retains a strong financial foundation and an attractive price tag. Let's delve into the specifics below.
ChartMill assigns a Valuation Rating to each stock, ranging from 0 to 10. This rating is calculated by analyzing different valuation elements, such as price to earnings and free cash flow, both in absolute terms and relative to the market and industry. In the case of NASDAQ:CPRX, the assigned 8 reflects its valuation:
ChartMill assigns a Profitability Rating to every stock. This score ranges from 0 to 10 and evaluates the different profitability ratios and margins, both absolutely, but also relative to the industry peers. NASDAQ:CPRX scores a 8 out of 10:
To gauge a stock's financial health, ChartMill utilizes a Health Rating on a scale of 0 to 10. This comprehensive evaluation encompasses liquidity and solvency, both in absolute terms and in comparison to industry peers. NASDAQ:CPRX has earned a 8 out of 10:
To evaluate a stock's growth potential, ChartMill utilizes a Growth Rating on a scale of 0 to 10. This comprehensive assessment considers various growth aspects, including historical and estimated EPS and revenue growth. NASDAQ:CPRX has achieved a 9 out of 10:
More Decent Value stocks can be found in our Decent Value screener.
Check the latest full fundamental report of CPRX for a complete fundamental analysis.
This is not investing advice! The article highlights some of the observations at the time of writing, but you should always make your own analysis and invest based on your own insights.
NASDAQ:CPRX (6/6/2025, 11:58:06 AM)
25.895
+0.54 (+2.11%)
Find more stocks in the Stock Screener
CATALYST PHARMACEUTICALS (CPRX) meets CANSLIM criteria with strong earnings growth, high relative strength, and solid fundamentals. A technical uptrend and reasonable valuation add to its appeal.
CATALYST PHARMACEUTICALS INC (CPRX) meets key growth criteria from Louis Navellier’s strategy, with strong earnings, revenue growth, and solid financial health. A detailed analysis highlights its potential for investors.
Catalyst Pharmaceuticals (CPRX) shows strong fundamentals, high profitability, and zero debt, making it a compelling choice for quality investors. The stock trades at reasonable valuations with solid growth prospects.
CATALYST PHARMACEUTICALS (CPRX) shows strong growth, profitability, and a bullish technical setup, making it a stock to watch in the biotech sector.
CATALYST PHARMACEUTICALS (CPRX) shows strong earnings momentum and a bullish technical setup, making it a candidate for high-growth investors.